Navigation Links
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Date:2/24/2009

ALISO VIEJO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced fourth quarter and full year financial results for 2008.

"With our new strategic initiatives beginning to take hold in the fourth quarter, we continue to make strides in staging Valeant for sustainable future growth," said J. Michael Pearson, chairman and chief executive officer. "We added to our future revenue and cash flow potential by acquiring three solid dermatology businesses, while we continue to see the impact of our cost reduction efforts. We exceeded our goal of $0.60 - $0.80 cash earnings per share for 2008 and expect this solid progress to continue into 2009."

New Segment Information:

We restructured our organization in the fourth quarter of 2008 in order to improve our execution and align our resources and product development efforts in the markets in which we operate. Our products are sold through three new segments comprising of Specialty Pharmaceuticals, Branded Generic - Europe and Branded Generic - Latin America. The Specialty Pharmaceuticals segment includes product revenues primarily from the U.S., Canada, Australia and divested businesses located in Argentina, Uruguay and Asia. The Branded Generic - Europe segment includes product revenues from branded generic pharmaceutical products primarily in Poland, Hungary, the Czech Republic and Slovakia. The Branded Generic - Latin America segment includes product revenues from branded generic pharmaceutical products primarily in Mexico and Brazil.

Revenues:

Total revenue was $183.0 million in the fourth quarter of 2008 as compared to $188.9 million in the fourth quarter of 2007.

Specialty Pharmaceutical product sales were $89.2 million in the fourth quarter of 2008, as co
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2010)... that may help fill a critical need in stem ... School of Medicine have demonstrated that skin cells found ... pluripotency, where they have characteristics similar to human embryonic ... of cell in the human body. The study is ... next issue of the journal Cellular Reprogramming , ...
(Date:3/15/2010)... Normal individuals who scored high on a measure of ... to a brain imaging study by researchers at Vanderbilt ... in the brain,s reward system that may underlie vulnerability ... study in the current issue of the journal ... on Drug Abuse (NIDA), a component of the National ...
(Date:3/15/2010)... BRUNSWICK, N.J. , March 15 ... statewide female-specific AIDS service organization, has launched "I Stand ... intended to mobilize families, individuals, corporations, social service agencies, ... up for the lives of women in NJ. At ... proportion of women living with AIDS in the nation. ...
(Date:3/15/2010)... [NLA] was recently featured by Lloyd,s of London in their electronic market ... insurance market. The article featuring New Life was in response to the recent press ... introduce the nations first in vitro fertilization insurance program. , ... ... , ...
(Date:3/15/2010)... Fla. (March 15, 2010)Patient selection is key ... interventional radiologists in individuals with painful osteoporotic ... to conventional medical therapyto be effective and ... than 1,500 persons who were followed over ... radiologist and other medical experts in treating ...
Breaking Medicine News(10 mins):Health News:Amniotic fluid cells more efficiently reprogrammed to pluripotency than adult cells 2Health News:Amniotic fluid cells more efficiently reprogrammed to pluripotency than adult cells 3Health News:Impulsive-antisocial personality traits linked to a hypersensitive brain reward system 2Health News:Impulsive-antisocial personality traits linked to a hypersensitive brain reward system 3Health News:For Women's History Month New Jersey Women and AIDS Network Launches 'I Stand With NJWAN' HIV Action and Awareness Campaign 2Health News:For Women's History Month New Jersey Women and AIDS Network Launches 'I Stand With NJWAN' HIV Action and Awareness Campaign 3Health News:Lloyd's of London News Features New Life Agency, Inc. 2Health News:Lloyd's of London News Features New Life Agency, Inc. 3Health News:Vertebroplasty for patients with osteoporosis provides effective pain relief 2Health News:Vertebroplasty for patients with osteoporosis provides effective pain relief 3
... teens. A report also disclosed that the recent sharp increases ... use decreased, and a gradual decline in use of inhalants ... ,These important declines in teen smoking did not ... have been making concerted efforts to bring down the unacceptably ...
... ensure the best outcome for the patient. This should ... avoid the side effects relating to these drugs. Several ... at Texas University it is necessary to find out ... differences between these drugs when it comes to reducing ...
... ‘Cyber City’ in Hyderabad, Andhra Pradesh chief minister Chandrababu ... up a ‘Pharma City’ in the port town of ... the state government hopes to attract global pharmaceutical companies ... the post-patent regime by 2005. The ‘Pharma City’ will ...
... to French researchers there is no obvious medical explanation ... patients during cardiac arrest. The near death experience (NDE) ... years.// It involves a feeling of disconnection from the ... cardiac arrest - and often progress down a tunnel ...
... demand for a new vaccine against childhood pneumonia, meningitis ... the country. Meanwhile, doctors are directing the supplies they ... of infection, such as those with sickle cell anemia, ... immune system. ,PREVNAR fights the bacterium streptococcus pneumoniae, ...
... despite a diet rich in butter and other fats, has ... another staple of the French diet. //Scientists say they have ... pigments known as polyphenols. ,Polyphenols inhibit the ... arteries. Polyphenols in red wine decreases the amount of the ...
Other Medicine News:
(Date:3/15/2010)... Adamas Pharmaceuticals, Inc., a privately held ... animal studies and in vitro ... (TCAD) therapy is superior relative to double combinations ... avian influenza viruses. Results of these studies were ... the XII International Symposium on Respiratory Viral Infections ...
(Date:3/14/2010)... , March 14 Results were presented today on behalf ... patients with diabetes that evaluated cardiovascular outcomes in three distinct studies – glycemic ... ACCORD Lipid study, Abbott issued the following statement: , ... ... ...
(Date:3/14/2010)... ATLANTA , March 14 /PRNewswire-FirstCall/ ... American College of Cardiology,s 59th annual scientific ... Valve Edge-to-Edge REpair STudy) trial demonstrated that ... primary safety and effectiveness endpoints(1), suggesting that ... an important treatment option for patients with ...
Breaking Medicine Technology:Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models 2Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models 3Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models 4Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models 5Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models 6Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use 2Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use 3New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 2New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 3New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 4New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 5New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 6New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 7New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 8New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition 9The Right Colorectal Cancer Test for the Right Patient 67818 1The Right Colorectal Cancer Test for the Right Patient 67818 2The Right Colorectal Cancer Test for the Right Patient 67818 3The Right Colorectal Cancer Test for the Right Patient 67818 4The Right Colorectal Cancer Test for the Right Patient 67818 5The Right Colorectal Cancer Test for the Right Patient 67818 6Bally Total Fitness Launches Music Focused Marketing Platform 67814 1Bally Total Fitness Launches Music Focused Marketing Platform 67814 2Bally Total Fitness Launches Music Focused Marketing Platform 67814 3AMA Honors Washington State Secretary of Health With Top Government Service Award 67810 1AMA Honors Washington State Secretary of Health With Top Government Service Award 67810 2AMA Honors Washington State Secretary of Health With Top Government Service Award 67810 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: